Oxaliplatin in Combination With Capecitabine and Concurrent Radiation Therapy in Non-Small Cell Lung Cancer

Phase I Study of Oxaliplatin (Eloxatin) and Capecitabine (Xeloda) and Concurrent Radiation Therapy (XELOX-RT) in Non-Small Cell Lung Cancer

Status

Terminated

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00268151

Enrollment

Registered

2005-12-22

Start date

2005-02-28

Completion date

Unknown

Last updated

2018-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma, Non-Small Cell Lung

Keywords

non-small cell lung cancer, oxaliplatin, capecitabine, XELOX-RT

Brief summary

The purpose of this study is to determine the most suitable dose of Oxaliplatin that can be safely given in combination with a low fixed dose of Capecitabine and a limited volume of radiation in patients with non-small cell lung cancer.

Detailed description

The purpose of this study is to determine the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of Oxaliplatin in combination with Capecitabine and radiation in subjects with non-small cell lung cancer.

Interventions

DRUGOxaliplatin

DRUGCapecitabine

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* histologically proven non-small cell lung cancer * inoperable Stage III A or B NSCLC * must have measurable disease by RECIST criteria * no more than one prior chemotherapy for advanced disease * ECOG Performance Status of 0, 1, or 2 * must be able to swallow pills or have a working gastric feeding tube and no evidence of malabsorption * negative serum beta-HCG test and under active contraception (for females of childbearing potential) * no known allergies to any of the study drugs * willingness to sign an informed consent

Exclusion criteria

* women who are pregnant or breastfeeding * ANC of less than 1500/mm3 * platelet count of less than 100,000/mm3 * estimated creatinine clearance of less than 50 cc/min (as measured by the Cockcroft-Gault equation) * bilirubin of less than 2mg/dl * SGPT of greater than 2x nl * peripheral neuropathy of Grade 2 or higher * more than one previous chemotherapy and previous radiation therapy to the chest * a history of CHF/MI or other significant cardiac history within the last six months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026